Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics
Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics
复制标题
DOI：
10.1016/j.coph.2016.07.013
复制
发表时间：
2016-10-01
影响因子：
4
通讯作者：
Liu, Mengfei
中科院分区：
文献类型：
--
作者：
Chang, Kyong-Mi;Liu, Mengfei
B型肝炎病毒（HBV）逃避、破坏、激活和调节宿主免疫组分，从而影响其自然史和疾病发病机制。我们对慢性病毒感染和肿瘤治疗中免疫相互作用的理解的最新进展适用于慢性B型肝炎（CH B）。随着近年来肿瘤免疫治疗的成功，人们对探索免疫治疗以实现慢性B型肝炎的持续和功能性治愈重新产生了兴趣。在这篇综述中，我们讨论了宿主的先天性和适应性免疫调节和致病性反应与HBV感染有关的方面。我们还强调了临床开发中治疗CHB的几种免疫调节方法。
Hepatitis B virus (HBV) evades, subverts, activates and regulates host immune components, thereby impacting its natural history and disease pathogenesis. Recent advances in our understanding of immune interactions in chronic viral infection and tumor therapy are applicable to chronic hepatitis B (CHB). With recent successes of tumor immunotherapy, there is a renewed interest in exploring immunotherapeutics in achieving sustained and functional cure of chronic hepatitis B. In this review, we discuss aspects of host innate and adaptive immune regulatory and pathogenic responses relevant for HBV infection. We also highlight several immune modulatory approaches in clinical development to treat CHB.